mitochondrial matrix (Gatley & Sherratt, 1979) , and has a low affinity for glycine (apparent K, 3.3 mM) (Bartlett & Gompertz, 1974) .
Methylenecyclopropylacetate, pent-4-enoate, cyclopropanecarboxylate, 3-methylbutyrate, 3-methylcrotonate and 2-methlbutyrate inhibited pyruvate carboxylation (Table 1) . These inhibitions could be due to antagonism of the activation of pyruvate carboxylase by acetyl-CoA by other acyl-CoA esters, or by depletion of acetyl-CoA concentrations, or by a combination of both effects. Indeed activation of purified pig liver pyruvate carboxylase by acetyl-CoA is competitively inhibited by pent-4-enoyl-CoA (apparent K , 2 0 ,~~) (Billington et al., 1978) . Acetyl-CoA could be formed from pyruvate by the action of pyruvate dehydrogenase or by the P-oxidation of endogenous fatty acids. The addition of 0.5 mwarsenite, which inhibits pyruvate dehydrogenase, suppressed pyruvate carboxylation. This effect was reversed by the addition of 1 mM-L-acetylcarnitine, which restores the matrix concentration of acetyl-CoA. Evidence for a direct inhibitory effect of some acyl-CoA esters was provided by the partial relief of inhibition in the presence of 5mM-glycine, except for that caused by pent-4-enoate (Table 1 ). This correlates with the specificity of glycine N-acylase for acyl-CoA esters (Bartlett 8c Gompertz, 1974; Sherratt, 1981) , and is presumably due to lowering of the steady-state concentration of acyl-CoA esters of the added fatty acids.
Addition of 3mM-ATP caused a 20-30% increase in the control rate of pyruvate carboxylation, and the carboxylic acids were also inhibitory under these conditions (results not shown). Liver mitochondria had an impaired respiratory control rate(stimu1ation of the basal rate by about 1.3) in the incubation medium used (Table I ) when compared with that in HC0,--free medium usually used for mitochondrial incubations (Holland & Sherratt, 1973) , and suggests a decreased efficiency of ATP synthesis.
Measurements of the activity of pyruvate carboxylase in intact mitochondria are difficult to interpret, since it is not possible to control the concentrations of all the substrates, effectors and inhibitors in the mitochondrial matrix. Nevertheless, these results provide evidence for a significant inhibition by some acyl-CoA esters that can be formed in vivo. They also have implications for understanding the mechanisms of metabolic disorders caused by some hypoglycaemic poisons, and of those associated with abnormal accumulations of acyl-CoA esters found in some inborn errors of metabolism. Valproate, administered as either sodium valproate or free valproic acid, is a widely used anticonvulsant that has been associated with hepatic failure (Editorial, 1980) . The mechanism of valproate-associated hepatic failure is unknown. Valproate is a simple branched-chain fatty acid, and a superficial analogy has been drawn with the effects of the toxic hypoglycaemic compounds hypoglycin and pent-4-enoate. It was suggested that valproate, or its metabolites, may cause a similar disturbance of intermediary metabolism. We therefore investigated the effects of valproate, in concentrations similar to those found in man during valproate therapy, on intermediary metabolism is isolated rat hepatocytes. The metabolic response of rats to a single dose of valproate was also studied. Hepatocytes were prepared from the livers of fed male Wistar rats (Seglen, 1972) . Pyruvate oxidation was determined by the production of "CO, from 10 mM-[ I-I4C1pyruvate (specific radioactivity 0.05 ,uCi/mmol). Palmitate oxidation was measured by using I .OmM-l 1-I4C ]palmitate (specific radioactivity I pCi/mmol) and the acid-soluble radioactivity formed was determined. Urea synthesis was determined by using 4 mMt-orthinine and 10 mM-L-glutamine as substrates in the presence of 5 mM-glucose. Gluconeogenesis was measured by determining the amount of I'4Clglucose formed from 2 m~-[U-'~Clalanine after a 20min incubation (Feliu et al., 1976) .
Male Wistar rats (200g), fed, or starved for 18 h, were given an intraperitoneal injection of sodium valproate ( 100mg/kg body wt. as a 0 . 1 4~ solution). Blood was taken from the tail vein for the determination of glucose, 3-hydroxybutyrate, pyruvate, lactate, alanine and glycerol by automated enzymic analysis (Lloyd et al., 1978) , and of acetoacetate by manual enzymic assay (Williamson et al., 1962) . Plasma valproate concentration was determined by the method of Chard (1976).
In isolated hepatocytes the oxidation of I 1 -"Clpyruvate and of I 1-"Clpalmitate and urea synthesis were inhibited by concentrations of valproate in the therapeutic range (Figs. I and 2). Glucagon increased the incorporation of I I-I4C lalanine into glucose (Fig. 2) . Both basal and glucagon-stimulated gluconeogenesis were inhibited by valproate in a concentration-dependent manner (Fig. 2) .
Valproate (100 mg/kg body wt.) decreased total ketone-body concentrations, both in fed and starved rats, with decreases in the 13-hydroxybutyratel/[acetoacetatel ratios. Valproate also caused decreases in blood glucose concentrations in starved rats. There were no significant changes in the concentrations of pyruvate, lactate, glycerol and alanine. The maximum decreases in blood glucose and ketone-body concentrations coincided with, or occurred slightly after, the maximum blood concentration of valproate.
Pyruvate and palmitate oxidation, urea synthesis and gluconeogenesis were inhibited by 3040% by valproate at concentrations between 0.1 and 10mM. All the metabolic disturbances in hepatocytes found can be explained by an increase in the ~acyl-CoAl/[CoAl ratio in the mitochondrial matrix, which may also be associated with a lower acetyl-CoA concentration.
(1) Pyruvate oxidation is inhibited at the stage of pyruvate dehydrogenase by several short-chain and mediumchain acyl-CoA esters (Gregersen, 1980) , and valproyl-CoA may inhibit similarly. (2) B-Oxidation of fatty acids, which involves several acyl-CoA esters as obligatory intermediates, is weakly competitively inhibited by several short-chain fatty acids, which form acyl-CoA esters in the mitochondrial matrix (Holland 8c Sherratt, 1973) , and this mechanism may explain inhibition of palmitate oxidation. (3) Decreased urea synthesis may be at the stage of carbamoyl phosphate synthase, since the conversion of ornithine into citrulline occurs in the mitochondrial matrix. (4) Inhibition of gluconeogenesis probably occurs at the stage of pyruvate carboxylase, which requires acetyl-CoA as an allosteric activator. An important factor in valproate-associated toxicity could be impairment of liver metabolism similar to that found in rat hepatocytes, and there are indications that this occurs in man. Although metabolic inhibitions caused by therapeutic concentrations of valproate are only partial and are normally well tolerated, they could nevertheless significantly impair liver function when there is an additional insult, such as may occur with multiple drug therapy or if there is already an inborn error of metabolism. The glyoxylate cycle is generally considered to be restricted to those micro-organisms which are able to grow on acetate as the sole source of carbon (Kornberg & Krebs, 1957) and plant tissues which have fat as their main food reserve (Beevers, 1969) . It has been accepted that animals, with the exception of nematodes, do not possess the unique enzymes (isocitrate lyase and malate synthase) of the glyoxylate cycle (Madsen, 1958) and are incapable of converting fat into carbohydrate. More recently, tentative evidence for the presence of isocitrate lyase in female rat dorsolumbar epidermis (Brown & Cox, 1968) , toad urinary bladder (Goodman et al., 1980) and fetal guinea-pig liver (Jones, 1980) prompted re-investigation in rat liver. Specifically, the suckling rat takes in a high-fat milk diet and is critically dependent on gluconeogenesis to maintain glucose homoeostasis (Snell & Walker, 1973; Snell, 1981 Snell, , 1982 . In these circumstances the conversion of fatty acids into glucose might be metabolically appropriate, particularly in view of an apparent calculated dietary short-fall of glucogenic precursors. Isocitrate lyase was therefore assayed during neonatal development in rat liver homogenates. Malate synthase was not assayed, since an alternative route for glyoxylate assimilation into glucose is available in neonatal rat liver (Snell, 1974 (Snell, , 1976 . Incubations contained 5 mM-sodium threoq-isocitrate, 3 0 m~-potassium phosphate buffer, pH 7.4,0.2 mM-dithiothreitol, 4 mMMgCI,, ImM-EDTA and 0.78g of liver in a total of 4ml and were continued for 10, 20 and 30min at 3OOC. To avoid ambiguous colorimetric methods, the glyoxylate formed in the isocitrate lyase reaction was determined enzymically by using glyoxylate reductase or lactate dehydrogenase. Although lactate dehydrogenase is not specific for glyoxylate, the reaction with glyoxylate is distinguishable from reactions with other (nonaldehydic) substrates, since it is inhibitable under specific conditions by Tris buffer (Rowsell et al., 1972a) . The recovery of glyoxylate from incubation systems containing HCI0,-deproteinized liver homogenate was quantitative by both enzymic determinations. Assays in liver from fetal (20 days gestation), 5-, 10-and 15-day-old, adult male and pregnant female rats failed to detect isocitrate lyase activity ((0.05 ,umol/ min per g of liver).
Incubations of liver homogenates with added glyoxylate (0.1 mM) led to its rapid removal, and this could be prevented by prior dialysis of the homogenate (Snell, 1971) . In case the inability to detect glyoxylate formation in isocitrate lyase assays was due to its rapid metabolic removal, liver homogenates were dialysed against homogenizing buffer (37.5 mwpotassium phosphate buffer, pH 7.4, 0.25 mwdithiothreitol, 5 mM-MgCI,, 1.25mM-EDTA) for 15 h before assay. Isocitrate lyase activity was again undetectable. It is concluded that rat liver does not possess isocitrate lyase activity at any stage of neonatal development. If the capability for glucose synthesis from fatty acids is present in the suckling rat, then it must involve pathways other than the glyoxylate cycle. One such speculative pathway has previously been proposed (Rowsell et al., 19726) and requires further investigation. The relationship between branched-chain amino acid metabolism and alanine synthesis and release in skeletal muscle has been emphasized in recent reviews (Snell, 1979 (Snell, , 1980 Snell & Duff, 1981 , 1982 . In addition, branched-chain amino acids, and leucine in particular, have an especial and unique role in muscle protein turnover by stimulating protein synthesis and inhibiting degradation (Buse & Reid, 1975; Li & Jefferson, 1978) . The hypolipidaemic drug clofibric acid (p-chlorophenoxymethylpropionic acid) interferes with branched-chain amino acid
VOl. 11 metabolism (Partridge, 198 1) and is associated with myopathy in man and experimental animals (Langer & Levy, 1968; Have1 & Kane, 1973; Abowizk ef al., 1979) . Clofibric acid inhibited leucine-stimulated alanine release in diaphragm, soleus and extensor digitorum longus muscles in vitro by 41,44 and 53% (Table I) . In contrast, valine-stimulated alanine release was not significantly affected by the drug. Tyrosine release, a measure of net protein breakdown, was stimulated by clofibric acid (by 32, 88 and 88% respectively in the three muscles) in the presence of leucine but not of valine. Further studies with diaphragm muscle, with 1 -i4C-labelled amino acids, showed that clofibric acid inhibited total leucine transamination (sum of release of I4CO2 and l-'4C-labelled 0x0 acids; Snell & Duff, 1982) by 63%, whereas inhibition of valine
